{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T17:19:16Z","timestamp":1780075156862,"version":"3.54.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["148361"],"award-info":[{"award-number":["148361"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000032","name":"CIHR III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000032","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015631","name":"Merck Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015631","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.antiviral.2022.105328","type":"journal-article","created":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T12:33:28Z","timestamp":1651149208000},"page":"105328","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["In vitro activity of letermovir against human cytomegalovirus isolates with different drug susceptibility phenotypes"],"prefix":"10.1016","volume":"202","author":[{"given":"Jocelyne","family":"Piret","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Goyette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3027-4662","authenticated-orcid":false,"given":"Guy","family":"Boivin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2022.105328_bib1","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2174\/187152609787847758","article-title":"Drug targets in cytomegalovirus infection","volume":"9","author":"Andrei","year":"2009","journal-title":"Infect. Disord. - Drug Targets"},{"key":"10.1016\/j.antiviral.2022.105328_bib2","series-title":"Viral Genome Replication","first-page":"481","article-title":"Viral DNA polymerase inhibitors","author":"Andrei","year":"2009"},{"key":"10.1016\/j.antiviral.2022.105328_bib3","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1128\/AAC.46.8.2365-2372.2002","article-title":"Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action","volume":"46","author":"Biron","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2022.105328_bib4","doi-asserted-by":"crossref","first-page":"6588","DOI":"10.1128\/AAC.01623-15","article-title":"Rapid in vitro evolution of human cytomegalovirus UL56 mutations that confer letermovir resistance","volume":"59","author":"Chou","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2022.105328_bib5","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.1128\/AAC.00511-13","article-title":"Cytomegalovirus UL97 kinase catalytic domain mutations that confer multidrug resistance","volume":"57","author":"Chou","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2022.105328_bib6","doi-asserted-by":"crossref","first-page":"4697","DOI":"10.1128\/AAC.03214-14","article-title":"Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing","volume":"58","author":"Chou","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2022.105328_bib7","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.antiviral.2012.05.013","article-title":"Effects on maribavir susceptibility of cytomegalovirus UL97 kinase ATP binding region mutations detected after drug exposure in vitro and in vivo","volume":"95","author":"Chou","year":"2012","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2022.105328_bib8","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1086\/375743","article-title":"Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus","volume":"188","author":"Chou","year":"2003","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2022.105328_bib9","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1128\/JVI.01787-07","article-title":"Accelerated evolution of maribavir resistance in a cytomegalovirus exonuclease domain II mutant","volume":"82","author":"Chou","year":"2008","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2022.105328_bib10","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1128\/AAC.00207-06","article-title":"Effect of cell culture conditions on the anticytomegalovirus activity of maribavir","volume":"50","author":"Chou","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2022.105328_bib11","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1086\/338362","article-title":"Cytomegalovirus UL97 phosphotransferase mutations that affect susceptibility to ganciclovir","volume":"185","author":"Chou","year":"2002","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2022.105328_bib12","doi-asserted-by":"crossref","first-page":"5927","DOI":"10.1128\/JVI.72.7.5927-5936.1998","article-title":"Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments","volume":"72","author":"Cihlar","year":"1998","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2022.105328_bib13","doi-asserted-by":"crossref","first-page":"3216","DOI":"10.1128\/JCM.01275-13","article-title":"Novel method based on \"en passant\" mutagenesis coupled with a Gaussia luciferase reporter assay for studying the combined effects of human cytomegalovirus mutations","volume":"51","author":"Drouot","year":"2013","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.antiviral.2022.105328_bib14","doi-asserted-by":"crossref","first-page":"535","DOI":"10.3851\/IMP3028","article-title":"Artesunate demonstrates in vitro synergism with several antiviral agents against human cytomegalovirus","volume":"21","author":"Drouot","year":"2016","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.antiviral.2022.105328_bib15","doi-asserted-by":"crossref","first-page":"4019","DOI":"10.1128\/AAC.00334-11","article-title":"Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet","volume":"55","author":"Gilbert","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2022.105328_bib16","doi-asserted-by":"crossref","first-page":"10884","DOI":"10.1128\/JVI.05265-11","article-title":"The novel anticytomegalovirus compound AIC246 (Letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase","volume":"85","author":"Goldner","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2022.105328_bib17","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.3389\/fmicb.2016.01317","article-title":"Detection of low frequency multi-drug resistance and novel putative maribavir resistance in immunocompromised pediatric patients with cytomegalovirus","volume":"7","author":"Houldcroft","year":"2016","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.antiviral.2022.105328_bib18","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1093\/cid\/ciaa1713","article-title":"Letermovir and maribavir for the treatment and prevention of cytomegalovirus infection in solid organ and stem cell transplant recipients","volume":"73","author":"Imlay","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2022.105328_bib19","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1093\/infdis\/jiz642","article-title":"De Novo genotypic heterogeneity in the UL56 region in cytomegalovirus-infected tissues: implications for primary letermovir resistance","volume":"221","author":"Jo","year":"2020","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2022.105328_bib20","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1128\/AAC.44.3.688-692.2000","article-title":"A standardized plaque reduction assay for determination of drug susceptibilities of cytomegalovirus clinical isolates","volume":"44","author":"Landry","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2022.105328_bib21","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/infdis\/jiv352","article-title":"Characterization of cytomegalovirus breakthrough events in a phase 2 prophylaxis trial of letermovir (AIC246, MK 8228)","volume":"213","author":"Lischka","year":"2016","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2022.105328_bib22","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1128\/AAC.05908-11","article-title":"In vitro evaluation of the activities of the novel anticytomegalovirus compound AIC246 (letermovir) against herpesviruses and other human pathogenic viruses","volume":"56","author":"Marschall","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2022.105328_bib23","doi-asserted-by":"crossref","first-page":"579","DOI":"10.3851\/IMP1565","article-title":"Opposite effect of two cytomegalovirus DNA polymerase mutations on replicative capacity and polymerase activity","volume":"15","author":"Martin","year":"2010","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.antiviral.2022.105328_bib24","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.jcv.2010.08.008","article-title":"Contrasting effects on ganciclovir susceptibility and replicative capacity of two mutations at codon 466 of the human cytomegalovirus UL97 gene","volume":"49","author":"Martin","year":"2010","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.antiviral.2022.105328_bib25","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jcv.2010.01.009","article-title":"Incidence and characterization of cytomegalovirus resistance mutations among pediatric solid organ transplant patients who received valganciclovir prophylaxis","volume":"47","author":"Martin","year":"2010","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.antiviral.2022.105328_bib26","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1093\/cid\/ciy706","article-title":"Maribavir for refractory or resistant cytomegalovirus infections in hematopoietic-cell or solid-organ transplant recipients: a randomized, dose-ranging, double-blind, phase 2 study","volume":"68","author":"Papanicolaou","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2022.105328_bib27","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.antiviral.2014.08.014","article-title":"Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism","volume":"111","author":"Pilorge","year":"2014","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2022.105328_bib28","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.antiviral.2019.01.011","article-title":"Clinical development of letermovir and maribavir: overview of human cytomegalovirus drug resistance","volume":"163","author":"Piret","year":"2019","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2022.105328_bib29","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01044-17","article-title":"Drug susceptibility and replicative capacity of multidrug-resistant recombinant human cytomegalovirus harboring mutations in UL56 and UL54 genes","volume":"61","author":"Piret","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2022.105328_bib30","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/rmv.615","article-title":"Function of human cytomegalovirus UL97 kinase in viral infection and its inhibition by maribavir","volume":"19","author":"Prichard","year":"2009","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.antiviral.2022.105328_bib31","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1086\/587106","article-title":"Artesunate as a potent antiviral agent in a patient with late drug-resistant cytomegalovirus infection after hematopoietic stem cell transplantation","volume":"46","author":"Shapira","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2022.105328_bib32","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02337-18","article-title":"Use of letermovir as salvage therapy for drug-resistant CMV retinitis: a case series","volume":"63","author":"Turner","year":"2019","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354222000973?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354222000973?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T12:35:40Z","timestamp":1759062940000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354222000973"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":32,"alternative-id":["S0166354222000973"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2022.105328","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro activity of letermovir against human cytomegalovirus isolates with different drug susceptibility phenotypes","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2022.105328","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105328"}}